Dr Reddy’s Laboratories ( ($RDY) ) just unveiled an update. On December 31, 2025, Dr. Reddy’s Laboratories disclosed that its wholly owned Swiss ...

FDA approval based on robust clinical studies and totality of evidence, which show no clinically meaningful differences from reference medicines Keren Haruvi, President Sandoz North America, said: ...

Approvals expand Amneal’s biosimilars portfolioCompany expects to commercialize six biosimilars across eight presentations by 2027BRIDGEWATER, ...

This month, Samsung Bioepis announced the European launch of Obodence (60 mg pre-filled syringe) and Xbryk (120 mg vial), ...

— Sandoz Canada has a leading biosimilars portfolio, with many more in the pipeline BOUCHERVILLE, Quebec, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Sandoz Canada, a leader in generics and biosimilars, today ...

Denosumab (Prolia) is a leading treatment for osteoporosis, but the rapid bone loss that can occur after discontinuing the RANK ligand inhibitor can be challenging to navigate. "I don't think we have ...

Please provide your email address to receive an email when new articles are posted on . “Although we observed an increasing number of osteonecrosis of the jaw cases in our daily practice during the ...

Boncresa is supplied as a 60mg/mL single-dose prefilled syringe for SC injection and Oziltus is supplied as a 120mg/1.7mL single-dose vial for SC injection. Boncresa is approved to treat ...

Please provide your email address to receive an email when new articles are posted on . A new clinical practice guideline from the Endocrine Society recommends treatment with IV bisphosphonates or ...

Results of a large phase III randomized controlled trial—recently published online in the Lancet—have shown that denosumab can delay the onset of bone metastasis in patients with castration-resistant ...

HOUSTON — High-risk osteoporosis patients who are transitioned to the antiresorptive drug denosumab (Prolia, Amgen) following a previous regimen that includes teriparatide (Forteo, Eli Lilly) show the ...